Big Pharma’s Latest Buy
MarketFoolery
The Motley Fool
4.7 • 1.7K Ratings
🗓️ 17 June 2019
⏱️ 16 minutes
🧾️ Download transcript
Summary
Pfizer buys Array Biopharma for $11.4 billion, sending shares of Array up 57%. Ron Gross analyzes the acquisition spree among big pharmaceutical companies. Target has a massive outage over the weekend, but we still have a few more questions about why. Plus, we dip into the Fool Mailbag and discuss the latest news from Papa John’s.
Thanks to Sprout Social for supporting Motley Fool. To learn how your brand can create real connection, visit sproutsocial.com/fool today.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Thanks to Sprout Social for supporting this episode of Market Flory. |
| 0:02.7 | Sprout Social offers businesses an intuitive platform to help build meaningful relationships |
| 0:08.0 | at scale on social. To learn how your brand can create real connection. |
| 0:13.0 | Visit sprout social.com slash fool today. |
| 0:17.0 | It's Monday, June 17th. |
| 0:20.0 | Welcome to market foolery. |
| 0:22.0 | I'm Chris Hill joining me in studio. Ron Gross. |
| 0:25.0 | How you doing? I'm good. I think we both had a good Father's Day. |
| 0:29.0 | It was really nice. Our respective Father's Days were good. |
| 0:32.0 | The weather was looking bad and it turned out wonderful. |
| 0:35.3 | Yeah, although am I the only one who napped on Father's Day? |
| 0:38.6 | That's the only one? |
| 0:39.8 | Maybe the only one in this room, but clearly not the only one. That's you know that's always a |
| 0:43.8 | good day when you can now. We've got retail news we've got restaurant news we're |
| 0:48.3 | going to dip into the full mailbag we're going to start with the deal of the day and |
| 0:52.0 | that is Pfizer buying array |
| 0:55.0 | bio-farma in a deal worth nearly 11.5 billion dollars array |
| 1:00.0 | bio-farma and if you're a shareholder congrats because that stocks up close to 60% |
| 1:06.7 | on this buyout they do a bunch of things I'm assuming that Pfizer bought a ray for the cancer treatment portfolio. |
| 1:15.2 | Absolutely and it's continuing a trend. |
| 1:19.5 | We've seen it lately with Merck, Eli Lillie, Bristol-Myers, several acquisitions in the cancer space. |
| 1:26.6 | Aray specifically has two drugs in their pipeline that focus on metastatic, easy for me to say melanoma and I think |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.